MedPath
Found 12 clinical trials|View Analysis
Sort by:

Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer

Phase 1
Recruiting
Conditions
Stage III Colorectal Cancer
Locally Advanced Colorectal Carcinoma
Recurrent Colorectal Carcinoma
Interventions
Drug: Aminolevulinic Acid
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Fluorescence-Guided Surgery
Procedure: Magnetic Resonance Imaging
Drug: Photodynamic Therapy
Procedure: Surgical Procedure
First Posted Date
2024-03-13
Last Posted Date
2024-08-05
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
21
Registration Number
NCT06307548
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

A Study for PD-1 Antibody JS001 in MSI-H Advanced or Recurrent Colorectal Cancer

Phase 2
Conditions
Colorectal Cancer
Interventions
Drug: JS001
First Posted Date
2019-10-08
Last Posted Date
2019-10-08
Lead Sponsor
Xu jianmin
Target Recruit Count
40
Registration Number
NCT04118933
Locations
🇨🇳

Zhongshan Hospital, Shanghai, Shanghai, China

Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)

Completed
Conditions
Advanced or Recurrent Colorectal Cancer
Interventions
First Posted Date
2014-03-18
Last Posted Date
2017-04-06
Lead Sponsor
Takeda
Target Recruit Count
3091
Registration Number
NCT02089737

A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

Phase 1
Completed
Conditions
Metastatic Colorectal Cancer
Interventions
First Posted Date
2009-04-02
Last Posted Date
2016-11-02
Lead Sponsor
Genentech, Inc.
Target Recruit Count
23
Registration Number
NCT00873756

Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer

Phase 2
Completed
Conditions
Colorectal Cancer
Interventions
First Posted Date
2004-04-27
Last Posted Date
2014-03-07
Lead Sponsor
University of Chicago
Target Recruit Count
16
Registration Number
NCT00003950
Locations
🇺🇸

University of Chicago Cancer Research Center, Chicago, Illinois, United States

🇺🇸

Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States

🇺🇸

University of Illinois at Chicago, Chicago, Illinois, United States

and more 7 locations

Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer

Phase 2
Conditions
Colorectal Cancer
First Posted Date
2004-02-12
Last Posted Date
2013-12-04
Lead Sponsor
Astex Pharmaceuticals, Inc.
Registration Number
NCT00005877
Locations
🇺🇸

SuperGen, Incorporated, Dublin, California, United States

Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer

Phase 3
Terminated
Conditions
Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage III Colon Cancer
Stage III Rectal Cancer
Stage IV Colon Cancer
Stage IV Rectal Cancer
Interventions
Drug: oxaliplatin
Drug: leucovorin calcium
Drug: capecitabine
Biological: bevacizumab
Drug: fluorouracil
Other: laboratory biomarker analysis
First Posted Date
2003-10-07
Last Posted Date
2013-01-25
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
2200
Registration Number
NCT00070122
Locations
🇺🇸

Southwest Oncology Group, San Antonio, Texas, United States

ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer

First Posted Date
2003-06-25
Last Posted Date
2013-03-21
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
22
Registration Number
NCT00026364
Locations
🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

Phase 2
Completed
Conditions
Colorectal Cancer
Interventions
First Posted Date
2003-01-27
Last Posted Date
2016-04-15
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
67
Registration Number
NCT00022698
Locations
🇺🇸

Markey Cancer Center at University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States

🇺🇸

Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States

🇺🇸

George Washington University Medical Center, Washington, District of Columbia, United States

and more 14 locations
© Copyright 2025. All Rights Reserved by MedPath